Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Guanethidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanethidine SCHEMBL122549 | 1.00 | CA12 (0.47) | CA12CA1CA2CA9NPC1 | |
| Guanethidine SCHEMBL2408085 | 1.00 | CA12 (0.47) | CA12CA1CA2CA9NPC1 | |
| Guanethidine SCHEMBL11873662 | 1.00 | CA12 (0.47) | CA12CA1CA2CA9NPC1 | |
| Sulfuric Acid SCHEMBL11726247 | 1.00 | CA12 (0.47) | CA12CA1CA2CA9NPC1 | |
| Guanethidine SCHEMBL9304898 | 0.98 | CA12 (0.46) | CA12CA1CA2CA9NPC1 | |
| Sulfuric Acid SCHEMBL11365479 | 0.98 | CA12 (0.46) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL8000929 | 0.91 | CA12 (0.53) | CA12CA1CA2CA9NPC1 | |
| Guanethidine SCHEMBL28254486 | 0.91 | CA12 (0.53) | CA12CA1CA2CA9NPC1 | |
| Guanethidine SCHEMBL34753 | 0.91 | CA12 (0.53) | CA12CA1CA2CA9NPC1 | |
| Guanethidine SCHEMBL28317238 | 0.90 | CA12 (0.45) | CA12CA1CA2CA9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1540 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3682454-B2 | METHOD FOR OBTAINING A SOLID TARGET FOR RADIOPHARMACEUTICALS PRODUCTION | ISTITUTO NAZ FISICA NUCLEARE (IT) | 2026-05-27 | — | — | EP | claimed |
| US-20260076976-A1 | TREATMENT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH GUANETHIDINE AND GUANADREL | M2SP LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-12396998-B2 | Treatment for heart failure with preserved ejection fraction with guanethidine and guanadrel | M2SP LLC (US) | 2025-08-26 | — | — | US | claimed |
| EP-4590307-A1 | TREATMENT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH GUANETHIDINE AND GUANADREL | M2SP LLC (US) | 2025-07-30 | — | — | EP | claimed |
| WO-2025131019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-26 | — | — | WO | claimed |
| US-20250177416-A1 | TREATMENT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH GUANETHIDINE AND GUANADREL | M2SP LLC | 2025-06-05 | — | — | US | claimed |
| US-20250177415-A1 | TREATMENT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH GUANETHIDINE AND GUANADREL | M2SP LLC | 2025-06-05 | — | — | US | claimed |
| CN-119997958-A | Treatment of ejection fraction retention heart failure with guanethidine and guanacol | M2SP有限责任公司 | 2025-05-13 | — | — | CN | claimed |
| US-20250082400-A1 | CHEMICAL ABLATION FORMULATIONS AND METHODS OF TREATMENTS FOR VARIOUS DISEASES | NEUROTRONIC, INC. | 2025-03-13 | — | — | US | claimed |
| EP-4464374-A2 | CHEMICAL ABLATION FORMULATIONS FOR VARIOUS DISEASES | Neurotronic, Inc. (US) | 2024-11-20 | — | — | EP | claimed |
| EP-0515546-A1 | TRIAZOLE ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO. INC. (US) | 1992-12-02 | — | — | EP | claimed |
| WO-1992020660-A1 | SUBSTITUTED 1-(2H)-ISOQUINOLINONES BEARING ACIDIC FUNCTIONAL GROUPS AS ANGIOTENSIN II ANTAGONISTS | MERCK & CO., INC. (US) | 1992-11-26 | — | — | WO | claimed |
| EP-0505098-A1 | Imidazole derivatives bearing acidic functional groups as angiotensin II antagonists | MERCK & CO. INC. (US) | 1992-09-23 | — | — | EP | claimed |
| WO-1991011999-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | claimed |
| WO-1991011909-A1 | TRIAZOLE ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | claimed |
| WO-1991012002-A1 | IMIDAZOLE ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | claimed |
| EP-0189861-A2 | Percutaneous absorption accelerator for ionic water-soluble medicine | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1986-08-06 | — | — | EP | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
| EP-0047339-B1 | DRUG FOR THE LOCAL TREATMENT OF GLAUCOMA | Dr. Thilo & Co. GmbH (DE) | 1984-02-08 | — | — | EP | claimed |
| US-4075335-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1978-02-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076976-A1 | TREATMENT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH GUANETHIDINE AND GUANADREL | PDE3B, PDE3A, PDE2A | CA12 2937/4885CA1 3907/4885CA2 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.